Biochemical and clinical response after umbilical cord blood transplant in a boy with early childhood-onset beta-mannosidosis. by Lund, Troy C. et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Neurology Faculty Papers Department of Neurology
7-1-2019
Biochemical and clinical response after umbilical
cord blood transplant in a boy with early
childhood-onset beta-mannosidosis.
Troy C. Lund
University of Minnesota
Weston P. Miller
Sangamo Therapeutics
Julie B. Eisengart
University of Minnesota
Katrina Simmons
Sanofi Genzyme
Laura Pollard
Greenwood Genetic Center
See next page for additional authors
Let us know how access to this document benefits you
Follow this and additional works at: https://jdc.jefferson.edu/neurologyfp
Part of the Neurology Commons, and the Pediatrics Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Neurology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Lund, Troy C.; Miller, Weston P.; Eisengart, Julie B.; Simmons, Katrina; Pollard, Laura; Renaud,
Deborah L.; Wenger, David A.; Patterson, Marc C.; and Orchard, Paul J., "Biochemical and clinical
response after umbilical cord blood transplant in a boy with early childhood-onset beta-
mannosidosis." (2019). Department of Neurology Faculty Papers. Paper 194.
https://jdc.jefferson.edu/neurologyfp/194
Authors
Troy C. Lund, Weston P. Miller, Julie B. Eisengart, Katrina Simmons, Laura Pollard, Deborah L. Renaud,
David A. Wenger, Marc C. Patterson, and Paul J. Orchard
This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/neurologyfp/194
Mol Genet Genomic Med. 2019;7:e712.    |  1 of 7
https://doi.org/10.1002/mgg3.712
wileyonlinelibrary.com/journal/mgg3
Received: 13 March 2019 | Accepted: 8 April 2019
DOI: 10.1002/mgg3.712  
O R I G I N A L  A R T I C L E
Biochemical and clinical response after umbilical cord blood 
transplant in a boy with early childhood‐onset beta‐mannosidosis
Troy C. Lund1  |   Weston P. Miller2 |   Julie B. Eisengart3  |   Katrina Simmons4 |   
Laura Pollard5 |   Deborah L. Renaud6 |   David A. Wenger7 |   Marc C. Patterson8 |    
Paul J Orchard1
This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
1Division of Pediatric Blood and Marrow 
Transplant, University of Minnesota, 
Minneapolis, Minnesota
2Sangamo Therapeutics, Richmond, 
California
3Division of Clinical Behavioral 
Neuroscience, Department of 
Pediatrics, University of Minnesota, 
Minneapolis, Minnesota
4Sanofi, Rare Disease Division, Sanofi 
Genzyme US, Bridgewater, New Jersey
5Biochemical Genetics 
Laboratory, Greenwood Genetic Center, 
Greenwood, South Carolina
6Department of Neurology, Department 
of Clinical Genomics, Department of 
Pediatrics, Mayo Clinic, Rochester, 
Minnesota
7Lysosomal Diseases Testing Laboratory, 
Department of Neurology, Sidney Kimmel 
Medical College, Thomas Jefferson 
University, Philadelphia, Pennsylvania
8Division of Child and Adolescent 
Neurology, Mayo Clinic, Rochester, 
Minnesota
Correspondence
Troy C. Lund, Pediatric Blood and Marrow 
Transplant Program, Leukodystrophy 
Center of Excellence, Stem Cell Institute, 
Global Pediatrics, University of Minnesota, 
MMC 366, 420 Delaware St SE, 
Minneapolis, MN 55455.
Email: lundx072@umn.edu
Abstract
Background: Deficiency in the enzyme β‐mannosidase was described over three 
decades ago. Although rare in occurrence, the presentation of childhood‐onset β‐
mannosidase deficiency consists of hypotonia in the newborn period followed by 
global development delay, behavior problems, and intellectual disability. No effec-
tive pharmacologic treatments have been available.
Methods: We report 2‐year outcomes following the first umbilical cord blood trans-
plant in a 4‐year‐old boy with early childhood‐onset disease.
Results: We show restoration of leukocyte β‐mannosidase activity which remained 
normal at 2 years posttransplant, and a simultaneous increase in plasma β‐mannosi-
dase activity and dramatic decrease in urine‐free oligosaccharides were also ob-
served. MRI of the brain remained stable. Neurocognitive evaluation revealed test 
point gains, although the magnitude of improvement was less than expected for age, 
causing lower IQ scores that represent a wider developmental gap between the pa-
tient and unaffected peers.
Conclusion: Our findings suggest that hematopoietic cell transplant can correct the 
biochemical defect in β‐mannosidosis, although preservation of the neurocognitive 
trajectory may be a challenge.
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1 |  INTRODUCTION
β‐Mannosidosis is a rare, autosomal‐recessive disorder of 
glycoprotein catabolism resulting from insufficient lyso-
somal β‐mannosidase activity (OMIM#248510) (Cooper, 
Hatton, Thornley, & Sardharwalla, 1990; Michalski & 
Klein, 1999). First described in a human case just over 
three decades ago(Wenger, Sujansky, Fennessey, & 
Thompson, 1986), relatively few reports of human disease 
have emerged since that time, with phenotypic variability 
in age‐of‐onset, rate of progression, and clinical severity 
(Gort et al., 2006; Labauge et al., 2009; Riise Stensland 
et al., 2008; Sedel et al., 2006). Within kinships, disease 
may not uniformly manifest, suggesting a role for modifi-
ers beyond residual enzyme activity (Alkhayat et al., 1998; 
Dorland et al., 1988; Kleijer et al., 1990). In severe cases, 
early childhood‐onset disease can lead to hypotonia, dys-
ostosis, intellectual disability, behavioral abnormalities, 
and peripheral neuropathy (Bedilu et al., 2002; Kleijer et 
al., 1990; Poenaru, Akli, Rocchiccioli, Eydoux, & Zamet, 
1992; Wijburg et al., 1992). Patients are primarily diag-
nosed by measuring β‐mannosidase activity in plasma or 
leukocytes and present with increase urinary disaccharides 
particularly mannosyl‐N‐acetylglucosamine. No definitive 
therapies exist beyond symptomatic treatment.
Allogeneic hematopoietic cell transplantation (HCT) 
benefits various neuropathic lysosomal and peroxiso-
mal inherited metabolic disorders (IMD) on the basis of 
metabolic cross‐correction. In the modern pediatric IMD 
transplant era, the use of human leukocyte antigen (HLA) 
histocompatible umbilical cord blood (UCB) is associated 
with favorable rates of engrafted survival (Boelens et al., 
2013; Martin et al., 2013; Miller et al., 2011). A recent 
report documents particularly favorable outcomes with 
HLA‐matched umbilical cord blood transplant (UCBT) 
in IMD (Mallhi et al., 2017). Similarly, low transplant 
regimen‐related toxicities have been reported with busul-
fan and fludarabine conditioning (Bartelink et al., 2014). 
Scant reports document benefit following HCT for other 
glycoproteinoses, but none describe transplantation for 
β‐Mannosidosis (Grewal et al., 2004; Miano et al., 2001; 
Mynarek et al., 2012; Vellodi et al., 1995). We report 2‐
year outcomes following HLA geno‐identical UCBT in a 
boy with early childhood‐onset disease.
2 |  CASE DESCRIPTION
A 4‐year, 6‐month‐old male was referred to us with newly 
diagnosed β‐mannosidosis. His birth history was notable for 
maternal preeclampsia necessitating C‐section at term. After 
an uneventful infancy, he was found to have hypotonia at 
8 months of age. He rolled at 11 months, sat alone at 12 months 
and walked at 22 months. He first spoke at 30 months. At age 
1 year, macrocephaly was noted, and an MRI revealed mild‐
to‐moderate cerebral hypomyelination. He was diagnosed with 
Autism Spectrum Disorder at age 2. Due to persistent language 
and motor developmental delays in the face of multiple rehabil-
itative therapies, repeat MRI at age 4 years, 3 months re‐dem-
onstrated poor myelination with symmetric T2 hyperintensities 
in the deep and subcortical white matter as well as the posterior 
limbs of the internal capsule (Figure 1). Additionally, he was 
noted to have a head circumference at the 93rd percentile. Given 
the constellation of findings, the possibility of a metabolic stor-
age disease was part of the differential diagnosis, and a leuko-
cyte oligosaccharidosis screen was performed that showed low 
leukocyte β‐mannosidase activity at 2.62 nmol hr‐1 mg‐1 (nor-
mal range 10–162.4 nmol hr‐1 mg‐1, Figure 2). Sequencing of 
MANBA (OMIM #248510) revealed compound heterozygous 
mutations: NP_005899.3:p.(Trp192Ter) (known pathogenic) 
and NP_005899.3:p.(Arg500His)(novel, but predicted to be 
pathogenic).
F I G U R E  1  Representative axial 
FLAIR sequences from brain MRI. 
Left MRI was performed at age 4 years, 
8 months (pre‐UCBT) and at age 6 years, 
8 months (2 years post‐UCBT) in a boy with 
β‐mannosidosis
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His exam prior to UCBT showed dysarthria, mild hypo-
tonia, mild dysmetria, and wide‐based gait with external hip 
rotation. An EEG, nerve conduction study (NCS), tympano-
gram, and otoacoustic emissions evaluation were all normal. 
Initial neurocognitive assessment prior to UCBT indicated 
slightly below average intellectual functioning and impaired 
language functioning.
3 |  METHODS
Transplant proceeded using a University of Minnesota 
Institutional Review Board approved protocol following pa-
rental consent. The conditioning regimen consisted of thy-
moglobulin (2.5 mg kg‐1dose‐1) IV once daily (−8, −7, −6 
and −5); and busulfan and fludarabine (40 mg m‐2 dose‐1), 
each IV once daily (−5, −4, −3 and −2). Daily busulfan 
pharmacokinetics were monitored for a total exposure of 
90 mg h L‐1. The graft was an 8/8 allele‐matched (HLA‐A, 
‐B, ‐C and –DRB1) unrelated umbilical cord blood unit 
with a total nucleated cell count (TNC) of 14  ×  107 cells/
kg. Graft versus host disease (GvHD) prophylaxis was with 
cyclosporine (days −2 to +180; goal trough 200–400 µg/L) 
and prednisolone (2 mg/kg through day + 28, then tapered to 
off over 2 weeks). Antimicrobial prophylaxis was with flu-
conazole and co‐trimoxazole. Engraftment kinetics, immune 
reconstitution, and donor hematopoietic chimerism were lon-
gitudinally monitored.
Leukocyte, plasma, and dried blood spot β‐mannosidase 
activity were measured before and after transplantation using 
the 4‐methylumbelliferyl substrate as previously described 
(Wenger et al., 1986). Urinary mannosyl‐N‐acetylglucos-
amine was measured using liquid chromatography tandem 
mass spectrometry (Huang, Cathey, Pollard, & Wood, 2018). 
Baseline and posttransplantation neuropsychological as-
sessments of intellectual function, adaptive behavior (i.e., 
functional life skills), memory, and visual‐motor skills (i.e., 
drawing; Beery & Beery, 2010; Driessen et al., 2003; Kan, 
F I G U R E  2  Mannosidase biomarkers pre‐ and post‐UCBT. Panels A‐C show beta‐mannosidase activity in the various biologic specimens 
indicated. The horizontal lines represent the limits of the normal range. Panel D shows urinary free oligosaccharide levels relative to an internal 
standard measured by LC‐MS/MS specific for beta‐mannosidosis. The time scales are given in months relative to UCBT
4 of 7 |   LUND et aL.
Melamed, & Offen, 2007; Kopen, Prockop, & Phinney, 1999), 
as well as brain MRI, were part of standard protocol for HCT. 
The neuropsychological evaluations use an age‐based stan-
dardized score with a population mean of 100 (standard devi-
ation = 15), and the descriptive ranges are: average (85–115), 
below average (70–84) and impaired (<70).
4 |  RESULTS AND DISCUSSION
Neutrophil and platelet engraftment occurred at days +13 and 
+21, respectively. Full (100%) donor myeloid chimerism was 
observed on day +21 and continues at most‐recent follow‐up 
(2 years). Donor T‐cell chimerism was initially 38% at day 
+21 and is 91% at 2 years post‐UCBT. At 1‐year posttrans-
plantation, absolute T‐ and B‐cell absolute counts returned to 
the normal range (which were similar to pretransplantation 
levels). No GvHD was observed and no infectious complica-
tions developed. Leukocyte β‐mannosidase activity normal-
ized at first posttransplant assessment (81.1 nmol hr‐1 mg‐1) 
and remains normal at 2 years post‐UCBT, and a simultane-
ous increase in plasma β‐mannosidase activity and dramatic 
decrease in urine free oligosaccharides were also observed 
(Figure 2).
Within the first several months of transplantation, the 
child experienced migraine headaches, nystagmus, worsen-
ing ataxia, loss of independent feeding, increased fearfulness 
and anxiety, anorexia requiring parenteral nutrition, and in-
tentional tremor (responsive to propranolol). Brain imaging 
again showed T2 white matter abnormalities that were stable 
in size and extent. By 6 months post‐UCBT, symptoms stabi-
lized, and the child was off parenteral nutrition support. One 
year after UCBT, significant improvements in gait, headache, 
tremor, nystagmus, fearfulness, and anxiety were noted. 
Brain MRI again remained stable and NCS remained nor-
mal (not shown). Two years after UCBT, continued improve-
ments were noted with respect to anxiety and gait. There were 
residual nystagmus, intention tremor, mild leg spasticity, and 
imbalance symptoms. Brain MRI re‐demonstrated stabiliza-
tion of white matter disease indicated by no change in the T2 
signal abnormalities seen previously (Figure 1).
Neuropsychological assessment (Table 1) revealed pre‐
UCBT adaptive behavior functioning was average overall, al-
though there was below average adaptive motor functioning. 
At 6 months following UCBT, adaptive behavior was signifi-
cantly impaired, yet it returned to baseline 2 years post‐UCBT 
with persistent impairment in motor functioning (Table 1). In 
terms of intellectual function, although overall IQ score de-
clined from baseline to 2 years post‐UCBT, analysis of raw 
score test points earned at each administration revealed either 
similar or greater points achieved at follow‐up. However, the 
magnitude of improvement was less than expected for age, 
causing the lower IQ score which represents a wider devel-
opmental gap between the patient and unaffected peers. This 
phenomenon is also true for a decline in visual‐motor integra-
tion score. Specifically, this child was initially mildly below 
average on this test, then impaired at 2‐year follow‐up, but he 
actually earned more raw score test points at 2‐year follow‐up 
than baseline. In fact, ataxia at 6 months post‐UCBT made 
completion of this test impossible, and thus the achievement 
of greater points on this test than baseline at 2  years post‐
UCBT is notable. In contrast, memory clearly declined from 
the average range at both baseline and 6 months follow‐up, to 
the impaired range at 2 years follow‐up, with less than half the 
T A B L E  1  Neuropsychological profile at baseline and longitudinally following UCBT in a 4‐year‐old boy with β‐Mannosidosis
Parameter
Pre‐UCBT 
(age = 4 years, 4 m)
6 months Post‐UCBT 
(age = 5 years, 2 m)
2 years Post‐UCBT 
(age = 6 years, 8 m)
Adaptive behavior skills
Communication 100 79 102
Daily living skills 95 69 89
Socialization 95 85 103
Motor 70 37 61
Adaptive behavior composite 88 64 86
Cognition
Nonverbal IQ 84 (41) N/A 64 (43)
Verbal IQ 78 (37) N/A 75 (57)
Full Scale IQ 80 N/A 68
Memory 100 (47) 100 (51) 65 (21)
Visual‐motor skills 80 (7) Unable 64 (10)
Note: Scores are age normalized (100 ± 15, with 85–115 the normal range). Scores in parentheses represent the number of items correctly answered on the test 
domains, that is, raw score. The Full Scale IQ score is a transformed score that is not directly derived from raw score points, and thus no parenthetical number is 
applicable.
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raw score test points earned at baseline. Memory challenges 
can be one of many factors contributing to slowed neurocog-
nitive development.
Early childhood‐onset β‐mannosidosis, though extremely 
rare, can manifest significant developmental delay and neu-
rologic abnormalities. Today no disease‐specific therapies 
exist. Allogeneic HCT has documented efficacy in numer-
ous lysosomal enzymopathies, as donor‐derived hematopoi-
etic cells are able to partially restore substrate catabolism. 
Further, HCT for lysosomal disorders involving neurocogni-
tive deterioration has been shown to arrest decline, although 
it has not reversed neurocognitive loss (Aldenhoven et al., 
2015; Hobbs et al., 1981; Krivit, Aubourg, Shapiro, & Peters, 
1999; Shapiro et al., 2015). While no reports of HCT for β‐
mannosidosis exist in the literature, several reports catalog 
benefit in other disorders of glycoprotein metabolism, sug-
gesting potential benefit for the disease. As favorable en-
grafted survival rates are observed with HLA geno‐identical 
UCBT in the modern era, we deemed the risks of treatment 
failure to be acceptably low.
Despite rapid normalization of leukocyte β‐mannosidase 
activity, our patient experienced acute clinical neurological 
worsening in the immediate posttransplantation period, be-
fore gradually returning to near‐baseline performance. Such 
posttransplantation course (acute, transient neurologic wors-
ening) is not unusual for patients with other neuropathic IMD 
and may represent reversible effects from medications for 
conditioning or use of calcineurin inhibitors in the prevention 
of GvHD.
Consistent with stable MRI between baseline and 2‐year 
follow‐up, the boy's neurocognitive performance does not 
provide evidence of active deterioration or skill loss, with 
the exception of memory function. Overall, his neurocogni-
tive trajectory has not aligned with age‐level expectations, 
and therefore his scores are all generally lower. This pat-
tern of lower post‐UCBT performance even after an intact 
pre‐UCBT baseline is seen in other neuropathic IMD such 
as Hurler syndrome and cerebral adrenoleukodystrophy 
(Aldenhoven et al., 2015; Coletti et al., 2015; Grosse, Lam, 
Wiggins, & Kemper, 2017; Pierpont et al., 2017; Shapiro 
et al., 2015). Longer term examination of neurocognitive 
function in other IMD post‐HCT suggests stabilization of 
neurocognition, provided that intervention occurred early 
enough in the disease process. Given the progressive na-
ture of these conditions, earlier treatment is associated with 
better neurocognitive outcomes, as disease burden is inter-
rupted prior to a severe level of accumulation and neurocog-
nitive damage(Aldenhoven et al., 2015; Grosse et al., 2017; 
Muenzer, Wraith, Clarke, & International Consensus Panel 
on Management and Treatment of Mucopolysaccharidosis 
I, 2009; Pierpont et al., 2017; Poe, Chagnon, & Escolar, 
2014; Shapiro et al., 2015). As this is the first report of 
UCBT for β‐mannosidosis, it will be critical to pursue 
further follow‐up in this child to determine if he continues 
to acquire neurocognitive skills, versus a developmental 
stagnation or actual skill loss. This follow‐up may help to 
clarify the impact of his baseline age and disease severity 
on his longer term outcomes. It may also clarify whether 
relative gains in other aspects of his overall neurologic 
status might be possible with sustained provision of func-
tional enzyme from the UCB graft.
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